FDA again delays promised social media guidance

Share this article:
The FDA has once again postponed the release of its first draft guidance for social media.

The federal agency was supposed to release the guidelines in late December, but stated at the time that it would delay the release of the first draft guidance until the first quarter of 2011.

Now that's been put on hold.

In a statement, the FDA said: “It is difficult to provide a timeframe for the issuance of our guidances due to the extensive work and review process, or ‘Good Guidance Practices' (GGPs), which ensures that FDA's stakeholders are provided well vetted guidances articulating FDA's current thinking on a topic.”

The most recent statement said that social media guidances will focus on six areas: responding to unsolicited requests, fulfilling regulatory requirements when using tools associated with space limitations, fulfilling post-marketing submission requirements, on-line communications for which manufacturers, packers, or distributors are accountable, and use of links on the Internet and correcting misinformation.

Emily Downward, senior VP of Edelman Digital Health, says PR pros are eagerly awaiting the release of the FDA's guidelines on social media in order to provide better counsel to their clients.

“It makes it more of a challenge without the guidelines,” she says. “The only guidelines we're getting is through warning letters. We equate [a lack of formal guidelines] with going through an obstacle course with a blindfold on. You don't know what to do until you hit the wall.”

Asked what has been the biggest challenging about developing the guidelines, the FDA spokesperson added: “We are taking into consideration the input from within and outside FDA, including testimony and comments from the Part 15 hearing (from November 2009), to develop multiple guidances on concepts that have long-term applicability so that they will not become quickly outdated as the tools and technology evolve.”

Editor's note: This story originally appeared in PRWeek, at prweekus.com (subscription required).
Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.